Last reviewed · How we verify
NCT07527884
The Effect of Radiotherapy After Separation Surgery for Spinal Metastases
NA trial testing radiotherapy in Spinal Metastases in 130 participants. Not yet recruiting.
1 May 2028
Quick facts
| Lead sponsor | Shanghai Changzheng Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 130 |
| Start date | 1 May 2026 |
| Primary completion | 1 May 2028 |
| Estimated completion | 30 June 2028 |
Drugs / interventions tested
- radiotherapy — full drug profile →
Conditions studied
- Spinal Metastases — all drugs for Spinal Metastases →
- Spinal Tumor — all drugs for Spinal Tumor →
- Radiotherapy — all drugs for Radiotherapy →
- Separation Surgery — all drugs for Separation Surgery →
Sponsor
Shanghai Changzheng Hospital
Who can join
18 and older, any sex, with Spinal Metastases or Spinal Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this clinical study is to explore the impact of whether radiotherapy is administered after spinal metastasis surgery on the prognosis and survival of patients, to describe the clinical outcomes, and to optimize future clinical decisions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07527884
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of radiotherapy
Trials testing the same drug.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
- NCT07282483 — Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer P · Phase 2 · recruiting
- NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting
- NCT07477626 — Radiotherapy After Prostatectomy for Node Positive Prostate Cancer · Phase 3 · active not recruiting
Other recruiting trials for Spinal Metastases
Currently open trials in the same condition.
- NCT06548061 — D20054;LITT for Spine Tumors · NA · recruiting
- NCT06244264 — The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis · NA · recruiting
- NCT06120426 — En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor · recruiting
- NCT05575323 — Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases · NA · recruiting
- NCT07429422 — SBRT Technique Implementation for Spinal Metastases Irradiation · NA · recruiting
Other Shanghai Changzheng Hospital trials
Trials by the same sponsor.
- NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
- NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
- NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting
- NCT07105644 — Observational Study of Sacral Nerve Function After Sacral Tumor Resection · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07527884 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07527884.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing